| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.075 | 0.2 |
| mRNA | AZD6244 | FIMM | pan-cancer | AAC | -0.25 | 0.2 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.24 | 0.2 |
| mRNA | ciclopirox | CTRPv2 | pan-cancer | AAC | 0.046 | 0.2 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.05 | 0.2 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |